Impact of bacteremia on the pathogenesis of experimental pneumococcal meningitis

Journal of Infectious Diseases

Volumn 197, Issue 2, 2008, Pages 235-244

  Brandt, Christian T ^a,b   Holm, David ^c   Liptrot, Matthew ^c   Østergaard, Christian ^a,d   Lundgren, Jens D ^b   Frimodt Møller, Niels ^a   Skovsted, Ian C ^a   Rowland, Ian J ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; PNEUMOCOCCAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL MENINGITIS; BLOOD BRAIN BARRIER; BRAIN; BRAIN EDEMA; BRAIN VENTRICLE; CEREBROSPINAL FLUID; CONCURRENT INFECTION; CONTROLLED STUDY; EXPERIMENTAL INFECTION; LABORATORY TEST; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PRIORITY JOURNAL; RAT; SEROTYPING; STATISTICAL SIGNIFICANCE; ANIMAL; BLOOD; HOSPITALIZATION; HUMAN; IMMUNOLOGY; INFLAMMATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; STREPTOCOCCUS PNEUMONIAE; WISTAR RAT;

ANIMALS; BACTEREMIA; BLOOD; BLOOD-BRAIN BARRIER; BRAIN; BRAIN EDEMA; CEREBROSPINAL FLUID; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MENINGITIS, PNEUMOCOCCAL; MOTOR SKILLS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; STREPTOCOCCUS PNEUMONIAE;

EID: 39149099799     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/524874     Document Type: Article

References (29)

1. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849-59.
2. Brandt CT, Lundgren JD, Lund SP, et al. Attenuation of the bacterial load in blood by pretreatment with granulocyte-colony-stimulating factor protects rats from fatal outcome and brain damage during Streptococcus pneumoniae meningitis. Infect Immun 2004; 72:4647-53.
3. Brandt CT, Frimodt-Moller N, Lundgren JD, et al. Evaluation of antipneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. J Antimicrob Chemother 2006; 58:1291-4.
4. Brandt CT, Lundgren JD, Frimodt-Moller N, et al. Blocking of leukocyte accumulation in the cerebrospinal fluid augments bacteremia and increases lethality in experimental pneumococcal meningitis. J Neuroimmunol 2005; 166:126-31.
5. Koedel U, Rupprecht T, Angele B, et al. MyD88 is required for mounting a robust host immune response to Streptococcus pneumoniae in the CNS. Brain 2004; 127:1437-45.
6. Rupprecht TA, Angele B, Klein M, et al. Complement C1q and C3 are critical for the innate immune response to Streptococcus pneumoniae in the central nervous system. J Immunol 2007; 178:1861-9.
7. Orihuela CJ, Fillon S, Smith-Sielicki SH, et al. Cell wall-mediated neuronal damage in early sepsis. Infect Immun 2006; 74:3783-9.
8. Bogdanski R, Blobner M, Becker I, Hänel F, Fink H, Kochs E. Cerebral histopathology following portal venous infusion of bacteria in a chronic porcine model. Anesthesiology 2000; 93:793-804.
9. Papadopoulos MC, Davies DC, Moss RF, Tighe D, Bennett ED. Pathophysiology of septic encephalopathy: a review. Crit Care Med 2000; 28:3019-24.
10. Wellmer A, von Mering M, Spreer A, et al. Experimental pneumococcal meningitis: impaired clearance of bacteria from the blood due to increased apoptosis in the spleen in Bcl-2-deficient mice. Infect Immun 2004; 72:3113-9.
11. Leib SL, Kim YS, Ferriero DM, Täuber MG. Neuroprotective effect of excitatory amino acid antagonist kynurenic acid in experimental bacterial meningitis. J Infect Dis 1996; 173:166-71.
12. Leib SL, Leppert D, Clements J, Täuber MG. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 2000; 68:615-20.
13. Østergaard C, O'Reilly T, Brandt C, Frimodt-Moller N, Lundgren JD. The influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniae meningitis. BMC Infect Dis 2006; 6:78.
14. Brandtzaeg P, Ovstebøo R, Kierulf P. Compartmentalization of lipopolysaccharide production correlates with clinical presentation in meningococcal disease. J Infect Dis 1992; 166:650-2.
15. Sande MA, Täuber MG. Pneumococcal meningitis: current pathophysiologic concepts. Microb Drug Resist 1999; 5:295-9.
16. Wispelwey B, Lesse AJ, Hansen EJ, Scheld WM. Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. J Clin Invest 1988; 82:1339-46.
17. Tuomanen EI, Saukkonen K, Sande S, Cioffe C, Wright SD. Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes. J Exp Med 1989; 170:959-69.
18. Sáez-Llorens X, Jafari HS, Severien C, et al. Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis. J Clin Invest 1991; 88:2003-11.
19. Ostergaard C, Yieng-Kow RV, Benfield T, Frimodt-Møller N, Espersen F, Lundgren JD. Inhibition of leukocyte entry into the brain by the selectin blocker fucoidin decreases interleukin-1 (IL-1) levels but increases IL-8 levels in cerebrospinal fluid during experimental pneumococcal meningitis in rabbits. Infect Immun 2000; 68:3153-7.
20. Paul R, Winkler F, Bayerlein I, Popp B, Pfister HW, Koedel U. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis. J Infect Dis 2005; 191:776-82.
21. Echchannaoui H, Frei K, Schnell C, Leib SL, Zimmerli W, Landmann R. Toll-like receptor 2-deficient mice are highly susceptible to Streptococcus pneumoniae meningitis because of reduced bacterial clearing and enhanced inflammation. J Infect Dis 2002; 186:798-806.
22. Koedel U, Angele B, Rupprecht T, et al. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol 2003; 170:438-44.
23. Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2:721-36.
24. Brandt CT, Simonsen H, Liptrot M, et al. In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging. BMC Med Imaging 2008 (in press).
25. Scheld WM, Dacey RG, Winn HR, Welsh JE, Jane JA, Sande MA. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis: alterations with penicillin and methylprednisolone. J Clin Invest 1980; 66:243-53.
26. Malipiero U, Koedel U, Pfister HW, et al. TGFβ receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. Brain 2006; 129:2404-15.
27. Braun JS, Novak R, Herzog KH, Bodner SM, Cleveland JL, Tuomanen EI. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 1999; 5:298-302.
28. Weber JR, Tuomanen EI. Cellular damage in bacterial meningitis: an interplay of bacterial and host driven toxicity. J Neuroimmunol 2007; 184:45-52.
29. Loeffler JM, Ringer R, Hablützel M, Täuber MG, Leib SL. The free radical scavenger α-phenyl-tert-butyl nitrone aggravates hippocampal apoptosis and learning deficits in experimental pneumococcal meningitis. J Infect Dis 2001; 183:247-52.